Carbimazole: increased risk of congenital malformations - strengthened advice on contraception (MHRA Drug Safety Update)

The MHRA has released a Drug Safety Update stating women of childbearing potential should use effective contraception during treatment with carbimazole.

Carbimazole is associated with an increased risk of congenital malformations, especially when administered in the first trimester of pregnancy, and at high doses (15mg or more daily).

Further information, including advice for healthcare professionals, is available on the MHRA website.